This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hollenberg, S. M. Articles by Costanzo, M. R. Search for Related Content PubMed PubMed Citation Articles by Hollenberg, S. M. Articles by Costanzo, M. R. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Transplantation Vascular Diseases Hazardous Substances DB NITROGLYCERIN Related Collections Pathophysiology Coronary imaging: angiography/ultrasound/Doppler/CC CV surgery: transplantation, ventricular assistance, cardiomyopathy Endothelium/vascular type/nitric oxide

(Circulation. 2001;104:3091.)
© 2001 American Heart Association, Inc.

Clinical Investigation and Reports

Coronary Endothelial Dysfunction After Heart Transplantation Predicts Allograft Vasculopathy and Cardiac Death

Steven M. Hollenberg, MD; Lloyd W. Klein, MD; Joseph E. Parrillo, MD; Markus Scherer, MD; Durand Burns, MD; Paul Tamburro, MD; Monica Oberoi, BS; Maryl R. Johnson, MD; Maria Rosa Costanzo, MD

From the Section of Cardiology, Rush-Presbyterian-St Luke’s Medical Center, Chicago, Ill.

Correspondence to Steven M. Hollenberg, MD, Section of Cardiology, Rush-Presbyterian-St Luke’s Medical Center, Chicago, IL 60612. E-mail shollenb{at}rush.edu

Background— Coronary endothelial dysfunction may be an early marker for cardiac allograft vasculopathy (CAV) in orthotopic heart transplant recipients. Using serial studies with intravascular ultrasound and Doppler flow-wire measurements, we have previously demonstrated that annual decrements in coronary endothelial function are associated with progressive intimal thickening. The present study tested whether endothelial dysfunction predicts subsequent clinical events, including cardiac death and CAV development.

Methods and Results— Seventy-three patients were studied yearly beginning at transplantation until a prespecified end point was reached. End points were angiographic evidence of CAV (>50% stenosis) or cardiac death (graft failure or sudden death). At each study, coronary endothelial function was measured with intracoronary infusions of adenosine (32-µg bolus), acetylcholine (54 µg over 2 minutes), and nitroglycerin (200 µg) into the left anterior descending coronary artery; intravascular ultrasound images and Doppler velocities were recorded simultaneously. Of the 73 patients studied, 14 reached an end point during the study (6 CAV and 8 deaths, including 4 with known CAV, 1 graft failure, and 3 sudden). On the last study performed, the group with an end point had decreased epicardial (constriction of 11.1±2.9% versus dilation of 1.7±2.2%, P=0.01) and microvascular (flow increase of 75±20% versus 149±16%, P=0.03) endothelium-dependent responses to acetylcholine compared with the patients who did not reach an end point. Responses to adenosine and nitroglycerin did not differ significantly.

Conclusions— Endothelial dysfunction, as detected by abnormal responses to acetylcholine, preceded the development of clinical end points. These data implicate endothelial dysfunction in the development of clinically significant vasculopathy and suggest that serial studies of endothelial function have clinical utility.

Key Words: acetylcholine • endothelium • transplantation • atherosclerosis • vasculature

This article has been cited by other articles:

				E. Raichlin, A. Prasad, W. K. Kremers, B. S. Edwards, C. S. Rihal, A. Lerman, and S. S. Kushwaha Sirolimus as primary immunosuppression is associated with improved coronary vasomotor function compared with calcineurin inhibitors in stable cardiac transplant recipients Eur. Heart J., June 1, 2009; 30(11): 1356 - 1363. [Abstract] [Full Text] [PDF]

				M. Kobayashi, Y. Tanoue, M. Eto, H. Baba, S. Kimura, S. Oda, K. Taniguchi, and R. Tominaga A Rho-kinase inhibitor improves cardiac function after 24-hour heart preservation. J. Thorac. Cardiovasc. Surg., December 1, 2008; 136(6): 1586 - 1592. [Abstract] [Full Text] [PDF]

				D. Schmauss and M. Weis Cardiac Allograft Vasculopathy: Recent Developments Circulation, April 22, 2008; 117(16): 2131 - 2141. [Abstract] [Full Text] [PDF]

				B. P. Griffith, M. Haddad, and R. S. Poston Immunobiology of Heart and Heart-Lung Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1513 - 1538. [Full Text]

				L. U. Nwakanma, A. S. Shah, J. V. Conte, and W. A. Baumgartner Heart Transplantation Card. Surg. Adult, January 1, 2008; 3(2008): 1539 - 1578. [Full Text]

				E. Raichlin, J.-H. Bae, Z. Khalpey, B. S. Edwards, W. K. Kremers, A. L. Clavell, R. J. Rodeheffer, R. P. Frantz, C. Rihal, A. Lerman, et al. Conversion to Sirolimus as Primary Immunosuppression Attenuates the Progression of Allograft Vasculopathy After Cardiac Transplantation Circulation, December 4, 2007; 116(23): 2726 - 2733. [Abstract] [Full Text] [PDF]

				A. J. Flammer, F. Hermann, I. Sudano, L. Spieker, M. Hermann, K. A. Cooper, M. Serafini, T. F. Luscher, F. Ruschitzka, G. Noll, et al. Dark Chocolate Improves Coronary Vasomotion and Reduces Platelet Reactivity Circulation, November 20, 2007; 116(21): 2376 - 2382. [Abstract] [Full Text] [PDF]

				C. Junor and K. C. Dellsperger Can we use surrogate vascular beds for evaluating endothelial function of the coronary vasculature in patients with cardiac allografts? Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H13 - H14. [Full Text] [PDF]

				P. H. McNulty, M. A. Tulli, B. J. Robertson, V. Lendel, L. A. Harach, S. Scott, and J. P. Boehmer Effect of simulated postprandial hyperglycemia on coronary blood flow in cardiac transplant recipients Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H103 - H108. [Abstract] [Full Text] [PDF]